Subscribe
22 September 2017Americas

Video interview: Allen & Overy on CRISPR evolution

To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Video interview: Allen & Overy on the UPC and CRISPR
19 September 2017   The Unified Patent Court is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
article
Video interview: Canada prepares for PTE system
5 September 2017   The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
Video interview: Allen & Overy on the UPC and CRISPR
19 September 2017   The Unified Patent Court is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
article
Video interview: Canada prepares for PTE system
5 September 2017   The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.

More on this story

Americas
Video interview: Allen & Overy on the UPC and CRISPR
19 September 2017   The Unified Patent Court is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.
article
Video interview: Canada prepares for PTE system
5 September 2017   The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic